Related Experiment Video
Updated: Feb 12, 2026

The Use of Drip Flow and Rotating Disk Reactors for Staphylococcus aureus Biofilm Analysis
Published on: December 27, 2010
Characterization of a New Staphylococcus aureus Kayvirus Harboring a Lysin Active against Biofilms
Luís D R Melo1, Ana Brandão2, Ergun Akturk3
1LIBRO-Laboratório de Investigação em Biofilmes Rosário Oliveira, Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4700-057, Braga, Portugal. lmelo@deb.uminho.pt.
Abstract:
Staphylococcus aureus is one of the most relevant opportunistic pathogens involved in many biofilm-associated diseases, and is a major cause of nosocomial infections, mainly due to the increasing prevalence of multidrug-resistant strains. Consequently, alternative methods to eradicate the pathogen are urgent. It has been previously shown that polyvalent staphylococcal kayviruses and their derived endolysins are excellent candidates for therapy. Here we present the characterization of a new bacteriophage: vB_SauM-LM12 (LM12). LM12 has a broad host range (>90%; 56 strains tested), and is active against several MRSA strains. The genome of LM12 is composed of a dsDNA molecule with 143,625 bp, with average GC content of 30.25% and codes for 227 Coding Sequences (CDSs). Bioinformatics analysis did not identify any gene encoding virulence factors, toxins, or antibiotic resistance determinants. Antibiofilm assays have shown that this phage significantly reduced the number of viable cells (less than one order of magnitude). Moreover, the encoded endolysin also showed activity against biofilms, with a consistent biomass reduction during prolonged periods of treatment (of about one order of magnitude). Interestingly, the endolysin was shown to be much more active against stationary-phase cells and suspended biofilm cells than against intact and scraped biofilms, suggesting that cellular aggregates protected by the biofilm matrix reduced protein activity. Both phage LM12 and its endolysin seem to have a strong antimicrobial effect and broad host range against S. aureus, suggesting their potential to treat S. aureus biofilm infections.
Insights
A novel bacteriophage, vB_SauM-LM12, and its endolysin show broad-spectrum activity against Staphylococcus aureus, including multidrug-resistant strains. These agents effectively reduce bacterial biofilms, offering potential for treating persistent infections.
Area of Science:
- Microbiology
- Bacteriophage Therapy
- Antimicrobial Resistance
Background:
- Staphylococcus aureus is a significant opportunistic pathogen causing biofilm-associated diseases and hospital-acquired infections.
- The rise of multidrug-resistant strains necessitates alternative therapeutic strategies.
- Bacteriophages and their endolysins have shown promise as anti-staphylococcal agents.
Purpose of the Study:
- To characterize a novel bacteriophage, vB_SauM-LM12 (LM12), and its encoded endolysin.
- To evaluate the efficacy of LM12 and its endolysin against Staphylococcus aureus biofilms.
- To assess the safety profile of the bacteriophage by analyzing its genome.
Main Methods:
- Isolation and characterization of bacteriophage vB_SauM-LM12.
- Genome sequencing and bioinformatics analysis of LM12.
- In vitro antibiofilm assays using LM12 and its purified endolysin.
- Evaluation of endolysin activity against different bacterial growth phases and biofilm structures.
Main Results:
- LM12 exhibits a broad host range, active against over 90% of tested S. aureus strains, including methicillin-resistant S. aureus (MRSA).
- The LM12 genome (143,625 bp dsDNA) lacks genes for virulence factors, toxins, or antibiotic resistance.
- Both LM12 and its endolysin significantly reduced viable bacterial cells and biofilm biomass, with the endolysin showing higher efficacy against planktonic and stationary-phase cells.
Conclusions:
- Bacteriophage LM12 and its endolysin possess potent antimicrobial and antibiofilm activities against Staphylococcus aureus.
- The broad host range and safety profile of LM12 suggest its potential as a therapeutic agent.
- Further investigation into the application of LM12 and its endolysin for treating S. aureus biofilm infections is warranted.
More Related Videos
Related Concept Videos
Biofilms
Co-activators and Co-repressors
tRNA Activation
Activation Energy
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
Secondary Active Transport

